毛利

Search documents
北方长龙(301357.SZ)2024年净利润为-1089.00万元,同比由盈转亏
Xin Lang Cai Jing· 2025-04-29 03:23
Core Insights - The company reported a total revenue of 108 million yuan for 2024, ranking 11th among disclosed peers, which represents a decrease of 27.15 million yuan or 20.13% year-on-year [1] - The net profit attributable to shareholders was -10.89 million yuan, ranking 7th among peers, a decline of 22.43 million yuan or 194.36% year-on-year [1] - The net cash flow from operating activities was -13.4 million yuan, ranking 7th among peers, a decrease of 12.9 million yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 9.03% [3] - The latest gross profit margin is 48.19% [3] - The latest return on equity (ROE) is -0.97%, ranking 7th among peers, a decrease of 1.98 percentage points year-on-year [3] - The diluted earnings per share is -0.11 yuan, ranking 7th among peers, a decline of 0.24 yuan or 184.62% year-on-year [3] - The total asset turnover ratio is 0.08 times, ranking 11th among peers, a decrease of 0.05 times or 36.45% year-on-year [3] - The inventory turnover ratio is 1.28 times, ranking 9th among peers, a decrease of 1.04 times or 44.82% year-on-year [3] Shareholder Structure - The number of shareholders is 10,700, with the top ten shareholders holding 72.9584 million shares, accounting for 76.64% of the total share capital [3] - The largest shareholder is Chen Yue, holding 46.25% [3] - The second-largest shareholder is Ningbo Zhongtie Changlong Investment Co., Ltd., holding 25.00% [3] Research and Development - The total R&D investment is 23.5338 million yuan, ranking 10th among peers, and represents a decrease of 3.0916 million yuan or 11.61% year-on-year [3] - The latest R&D investment ratio is 21.84% [3]
瑞德智能(301135.SZ)2024年净利润为3822.77万元、较去年同期下降6.49%
Xin Lang Cai Jing· 2025-04-29 03:23
2025年4月29日,瑞德智能(301135.SZ)发布2024年年报。 公司营业总收入为12.62亿元,在已披露的同业公司中排名第24。归母净利润为3822.77万元,在已披露 的同业公司中排名第30,较去年同报告期归母净利润减少265.11万元,同比较去年同期下降6.49%。经 营活动现金净流入为501.41万元,在已披露的同业公司中排名第31,较去年同报告期经营活动现金净流 入减少7194.44万元,同比较去年同期下降93.48%。 公司最新总资产周转率为0.69次,在已披露的同业公司中排名第20。最新存货周转率为6.70次。 公司股东户数为1.14万户,前十大股东持股数量为5849.19万股,占总股本比例为57.35%,前十大股东 持股情况如下: | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | T | 汪军 | 20.50% | | 2 | 佛山市瑞翔投资有限公司 | 13.43% | | 3 | 黄祖好 | 8.26% | | 4 | 潘卫明 | 3.27% | | 5 | *东弘德投资管理有限公司-广东弘德恒顺新材料创业投资合伙企业(有限合伙) | 2.78% ...
福斯特(603806):光伏胶膜单平净利环比显著提升 高端电子材料开始出货
Xin Lang Cai Jing· 2025-04-29 02:40
Core Viewpoint - The company released its Q1 2025 financial report, showing a revenue of 3.624 billion yuan, a year-on-year decrease of 31.89%, and a net profit attributable to shareholders of 401 million yuan, a year-on-year decrease of 23.08%, but a quarter-on-quarter increase of 709.79% [1][2]. Financial Performance - Q1 revenue was 3.624 billion yuan, down 31.89% year-on-year [2]. - Net profit attributable to shareholders was 401 million yuan, down 23.08% year-on-year, but up 709.79% quarter-on-quarter [2]. Gross Margin Analysis - The gross margin improved quarter-on-quarter, primarily due to the recovery in the gross margin of photovoltaic film, driven by rising prices of raw materials and film [3]. - The price of EVA particles has rebounded since Q4 of last year, leading to a price increase in photovoltaic film [3]. - Orders from overseas bases in Thailand and Vietnam are full, resulting in a supply-demand imbalance and price increases [3]. Outlook for the Year - The company expects a moderate recovery in the gross margin of photovoltaic film, with overseas revenue share continuing to rise [4]. - The Thai production base is set to start operations in May, which will increase the overseas production share to around 20%, potentially raising the overseas revenue share to 15%-20% for the year [4]. - The photovoltaic film industry is beginning to clear out, with 2-3 tier manufacturers controlling shipment volumes to reduce losses [4]. - The price of ordinary photosensitive dry film has bottomed out, and high-end products have started shipping, which is expected to increase the average price of electronic materials this year [4]. Profit Forecast - The company forecasts net profits attributable to shareholders for 2025-2027 to be 1.626 billion, 2.061 billion, and 2.4 billion yuan, with year-on-year growth rates of 24.34%, 26.75%, and 16.49% respectively [4]. - Earnings per share are projected to be 0.62, 0.79, and 0.92 yuan for the same period, corresponding to price-to-earnings ratios of 19.35, 15.27, and 13.11 times based on the closing market value on April 25 [4].
安琪酵母(600298):海外延续增长趋势 毛利率改善报表端兑现
Xin Lang Cai Jing· 2025-04-29 02:35
Core Insights - The company reported Q1 2025 results with revenue of 3.79 billion yuan, a year-on-year increase of 8.9%, and a net profit attributable to shareholders of 370 million yuan, up 16.0% year-on-year [1] Revenue Breakdown - In Q1 2025, overseas revenue continued to grow, with a quarter-on-quarter increase compared to Q4 2024 - By product: - Yeast and deep processing products generated revenue of 2.77 billion yuan, up 13.2% year-on-year - Sugar products generated revenue of 160 million yuan, down 60.7% year-on-year - Packaging products generated revenue of 100 million yuan, down 4.4% year-on-year - Food ingredients and other products generated revenue of 760 million yuan, up 44.1% year-on-year [2] - By region: - Domestic revenue was 2.10 billion yuan, down 0.3% year-on-year - Overseas revenue was 1.68 billion yuan, up 22.9% year-on-year, continuing the growth trend with improved quarter-on-quarter growth compared to Q4 2024 [2] Profitability and Cost Management - The company achieved a gross margin of 26.0%, an increase of 1.3 percentage points year-on-year, primarily due to a decrease in molasses costs - The selling, administrative, research and development, and financial expense ratios changed year-on-year as follows: - Selling expenses: +0.7 percentage points - Administrative expenses: -0.2 percentage points - Research and development expenses: -0.5 percentage points - Financial expenses: -0.5 percentage points, mainly due to increased foreign exchange gains - Asset impairment losses decreased by 0.5 percentage points year-on-year, mainly due to increased inventory write-downs - The net profit margin attributable to shareholders and the net profit margin excluding non-recurring items increased by 0.6 and 0.4 percentage points to 9.8% and 8.9%, respectively [2] Future Outlook - For 2025, the company expects overseas business growth to exceed 20%, continuing the previous growth trend - The overseas market still has significant growth potential, and with the expansion of overseas subsidiaries' production capacity, the company anticipates sustained growth - On the cost side, favorable raw material costs are expected to continue reflecting positively in the financial statements - Projected revenues for 2025-2027 are 16.89 billion, 18.67 billion, and 20.54 billion yuan, with year-on-year growth rates of 11.2%, 10.5%, and 10.0%, respectively - Projected net profits attributable to shareholders for 2025-2027 are 1.56 billion, 1.76 billion, and 1.91 billion yuan, with year-on-year growth rates of 17.7%, 13.1%, and 8.2%, respectively [3]
蓝箭电子(301348.SZ)2024年净利润为1511.18万元、较去年同期下降74.11%
Xin Lang Cai Jing· 2025-04-29 02:19
公司摊薄每股收益为0.08元,在已披露的同业公司中排名第97,较去年同报告期摊薄每股收益减少0.27元,同比较去年同期下降77.14%。 公司最新总资产周转率为0.38次,较去年同期总资产周转率减少0.11次,同比较去年同期下降22.42%。最新存货周转率为5.52次。 公司股东户数为3.02万户,前十大股东持股数量为1.03亿股,占总股本比例为51.38%,前十大股东持股情况如下: | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 王成名 | 15.8 | | 2 | 陈湛伦 | 9.86 | | 3 | 上海银圣宇企业管理咨询合伙企业(有限合伙) | 8.71 | | 4 | 张顺 | 7.55 | | 5 | 舒程 | 3.27 | | 6 | 东比邻投资基金管理有限公司-比邻创新(天津)股权投资基金合伙企业(有限合 | 3.04 | | | 伙) | | | 7 | 赵秀珍 | 0.98 | | 8 | 曾周洁 | 0.82 | | ਰੇ | 袁凤江 | 0.78 | | 10 | 陈鹏 | 0.54 | 2025年4月29日,蓝箭电子(301348.SZ)发布 ...
安达股份IPO:报告期内劳务派遣人数占比一度超四成 对大供应商采购数据披露存在差异
Mei Ri Jing Ji Xin Wen· 2025-04-28 14:15
Core Viewpoint - Andar Automotive Parts Co., Ltd. is pursuing an IPO on the Beijing Stock Exchange, showing a rising gross profit margin in its main business despite a declining average margin among comparable companies in the industry [1][2]. Group 1: Financial Performance - The gross profit margins for Andar from 2021 to the first half of 2024 are reported as 10.25%, 10.15%, 15%, and 18.17% respectively, indicating a continuous increase influenced by product structure, sales prices, and costs [2]. - In contrast, the average gross profit margins of comparable companies in the same period are 20.76%, 19.40%, 17.54%, and 17.24%, showing a downward trend [2]. Group 2: Labor Practices - The proportion of labor dispatch workers at Andar was over 40% as of August 31, 2023, with non-compliance issues noted in previous years [3]. - The average cost of labor dispatch workers was reported to be 23.93% lower than that of formal production employees [3]. Group 3: Supplier Relationships - Andar's second-largest supplier in 2022 was Lanxi Boyuan Metal Co., Ltd., with a procurement amount of 66.58 million yuan, which is nearly 10 million yuan higher than previously disclosed figures [5][7]. - Discrepancies were noted in procurement data, with Andar reporting a lower procurement amount for Boyuan Metal in earlier disclosures [7]. Group 4: Outsourcing and Related Parties - Andar has utilized external processing methods, with procurement amounts for outsourcing reported as 38.71 million yuan, 33.73 million yuan, 14.76 million yuan, and 3.08 million yuan over the specified periods [4]. - The company has shifted its electricity procurement to a related party, with amounts of 28.43 million yuan and 12.88 million yuan for 2023 and the first half of 2024 respectively [7].
春立医疗收盘下跌3.32%,滚动市盈率43.82倍,总市值54.77亿元
Jin Rong Jie· 2025-04-28 12:14
Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 14.28 yuan, down 3.32%, with a rolling PE ratio of 43.82 times and a total market value of 5.477 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Chunzhi Medical at the 85th position in the industry ranking [1] - As of the 2024 annual report, four institutions hold shares in Chunzhi Medical, with a total of 382,700 shares valued at 0.05 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for 2024 shows that the company achieved operating revenue of 806 million yuan, a year-on-year decrease of 33.32%, and a net profit of 125 million yuan, down 55.01%, with a gross profit margin of 66.63% [1]
创益通(300991) - 300991创益通2024年年度业绩说明会投资者关系活动记录表
2025-04-28 09:44
证券代码:300991 证券简称:创益通 深圳市创益通技术股份有限公司 投资者关系活动记录表 编号:2025-001 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他(请文字说明其他活动内容) | | 参与单位名称及人员姓名 | 线上参与公司2024年年度业绩说明会的投资者 | | 时间 | 2025年04月28日 15:00-17:00 | | 地点 | 价值在线(https://www.ir-online.cn/)网络互动 | | | 董事长兼总经理 张建明 | | | 独立董事 薛建中 | | 上市公司接待人员姓名 | 财务负责人兼董事会秘书 彭治江 | | | 保荐代表人 王昭 1.公司2024年业绩增长的主要原因是什么? | | | 答:您好,感谢您对公司的关注和支持。公司2024年度业绩增 | | 投资者关系活动主要内容 | 长的主要原因是:(1)受到宏观经济形势和消费电子行业回暖的 | | 介绍 | 影响,连接器行业的生产及销售规模都出现不同 ...
中海物业(02669):跟踪报告:经营效率提升,业绩增长保障性强
EBSCN· 2025-04-28 09:14
Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company demonstrates strong performance growth with improved operational efficiency and increased cash reserves, leading to a higher dividend payout ratio [2][3] - The main business segments, property management and community value-added services, show steady growth, contributing to 86% of total revenue [2] - The company has optimized its managed projects, enhancing operational efficiency and improving gross profit margins [3] - The company is backed by China Overseas Development and China State Construction Group, providing a rich resource for property management projects [4] Summary by Relevant Sections Financial Performance - In 2024, the company is projected to achieve revenue of 14 billion HKD, a year-on-year increase of 7.5%, with a gross profit of 2.33 billion HKD, up 12.4%, and a net profit attributable to shareholders of 1.51 billion HKD, reflecting a 12.5% increase [1] - The company plans to distribute a total dividend of 0.18 HKD per share for the year, a 29% increase compared to the previous year [1] Operational Efficiency - By the end of 2024, the company will manage an area of 430 million square meters, with new contracts signed for 74.1 million square meters, 63.3% of which comes from third parties [3] - The company has exited 44.5 million square meters of loss-making projects, optimizing its business structure and enhancing operational efficiency [3] Cash Flow and Dividends - As of the end of 2024, the company has cash and bank balances of 5.8 billion HKD, an increase of 13.1% from the previous year [3] - The dividend payout ratio for 2024 is set at 36.3%, an increase of 4.5 percentage points year-on-year [3] Profit Forecast and Valuation - The company’s net profit forecasts for 2025 and 2026 have been adjusted to 1.68 billion HKD and 1.87 billion HKD, respectively, with a new forecast for 2027 set at 2.04 billion HKD [4] - The projected price-to-earnings (P/E) ratios for 2024, 2025, and 2026 are 10, 9, and 8 times, respectively, indicating strong valuation attractiveness [4]
兰卫医学(301060.SZ)2025年一季报净利润为-808.09万元,同比由盈转亏
Xin Lang Cai Jing· 2025-04-28 02:36
2025年4月28日,兰卫医学(301060.SZ)发布2025年一季报。 公司营业总收入为3.51亿元,较去年同报告期营业总收入减少8555.62万元,同比较去年同期下降 19.60%。归母净利润为-808.09万元,在已披露的同业公司中排名第24,较去年同报告期归母净利润减 少915.26万元,同比较去年同期下降854.01%。经营活动现金净流入为165.81万元,在已披露的同业公 司中排名第18。 公司最新资产负债率为30.74%,在已披露的同业公司中排名第22,较上季度资产负债率增加0.13个百分 点。 公司最新毛利率为19.95%,在已披露的同业公司中排名第29,较上季度毛利率减少2.13个百分点,较去 年同期毛利率减少1.95个百分点。最新ROE为-0.49%,在已披露的同业公司中排名第25,较去年同期 ROE减少0.55个百分点。 公司摊薄每股收益为-0.02元,在已披露的同业公司中排名第25,较去年同报告期摊薄每股收益减少0.02 元,同比较去年同期下降851.85%。 公司最新总资产周转率为0.13次,较去年同期总资产周转率减少0.01次,同比较去年同期下降9.77%。 最新存货周转率为0. ...